https://www.selleckchem.com/pr....oducts/cucurbitacin-
The RP2Ds were temsirolimus 25mg +capecitabine 1000mg/m (Q2); and temsirolimus 25mg +capecitabine 750mg/m (Q3). Of the 38 patients evaluable for response, one had a partial response (PR) and 19 had stable disease (SD). The overall disease control rate was 52%. Five of the 20 patients with SD/PR maintained disease control for 6months. The combination of temsirolimus and capecitabine is safe on both a Q2-week and a Q3-week schedule. The combination demonstrated promising evidence of disease control in this highly refractory pop